Monoclonal antibodies next generation

Tomita, M. 2008. Next generation of monoclonal antibodies shortlisting lymphocytes via B-cell targeting. BlOforum Eur 4 33-34. 

Because of the limitations seen with the fully murine monoclonal antibodies the next generation of antibodies were chimeric antibodies (Table 26.2, Figure 26.2). Chimeric antibodies are constructed from variable regions derived from a murine source and constant regions derived from a human source. The chimeric antibodies show less of an immunogenic response than the fully murine antibodies, but human anti-chimeric antibody (FIACA) rates can still be high with these antibodies. The chimeric antibodies nevertheless have relative long serum half-lives (9.5 days for infliximab) relative to the fully murine antibodies because the Fc portion is human and can therefore bind to human FcRn in a manner similar to that of native antibodies. 

---